During the Obama presidency, the Affordable Care Act (ACA) gave the basic medicare protection to the needy people. After President Trump entered the White House, he repealed the Obama care right away. The dramatic reform of medical insurance in the United States (aka 美国医保) aroused heated public discussion.

Not only American citizens but international students have some comments as regards the change in their international student insurance (aka 留学生 保险), F-2 insurance (aka f2保险), OPT insurance (aka opt 保险), J1/J2 insurance (aka j1 j2 保险). Among all types of health insurance for international individuals, OPT insurance has the most “sensitive” changes, since OPT is the transition from the status of a student to a societal worker. Many terms in the previously recommended OPT insurance (aka opt保险推荐) plans must be changed.

The General Office of the State Council on Tuesday released a directive unveiling a series of major tasks in China’s bid to deepen the reform of its medical and healthcare system.

Stressing firm efforts to carry out the reform for the wellbeing of the people and address problems in healthcare accessibility and affordability, the document specified the priority and details of the tasks, and showed the country’s dedication to the reform. Among all fields that the tasks cover, some have stood out and already drawn considerable response from the public.

China will release a list of generic drugs by the end of June this year to guide enterprises to develop, register and produce urgently needed generic drugs for clinical use, public health and safety, according to the National Health Commission. Those on the list will be the first batch of generic drugs of which production will be encouraged, the commission said, adding that a renewed list would be released by the end of each year, starting from 2020.

With healthcare reform going deeper and a population increasingly ageing, China encourages both the creation of new drugs and the research and development of generic drugs, and strives to transform from a major drug making country to a country strong in medicine manufacturing. The list of generic drugs is among 15 regulations, of which the release by the end of this year has been listed as priorities in China’s medical and healthcare system reform in 2019.

Similar Posts